Form 4: Metagenomi Executive Matthew Wein Reports Stock and Option Awards
SEC Form 4 Filing
Matthew Wein, Vice President of Corporate Legal and Compliance, and Corporate Secretary at Metagenomi, reported the acquisition of restricted stock units and stock options.
Summary
- On April 1, 2024, Matthew Wein, an officer of Metagenomi, Inc., reported the acquisition of 10,397 shares of common stock in the form of restricted stock units (RSUs).
- These RSUs vest 25% on March 5, 2025, and the remaining 75% vest in 12 equal quarterly installments thereafter, contingent upon continued service with the company.
- Wein also acquired options to purchase 43,717 shares of common stock at an exercise price of $10.82 on April 1, 2024.
- These options vest 25% on February 1, 2025, and the remaining 75% vest in 36 equal monthly installments thereafter, contingent upon continued service with the company.
- Following these transactions, Wein directly owns 10,397 shares of common stock and options to purchase 43,717 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice, indicating confidence in the executive and aligning their interests with the company's success. There are no explicitly negative aspects presented in the filing.
Positives
- The granting of RSUs and stock options to a key executive like Matthew Wein can be seen as a positive sign, aligning his interests with the long-term success of Metagenomi.
- The vesting schedules for both the RSUs and stock options incentivize continued service and commitment from the executive.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued employment and company performance.
Industry Context
Stock and option awards are a common practice in the biotechnology industry to attract, retain, and incentivize key personnel. This filing reflects standard compensation practices for executives in publicly traded companies.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation components for executives in biotech companies like Metagenomi.
- Comparable companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options and RSUs as part of their executive compensation packages.
- The vesting schedules described are typical, with initial vesting occurring after one year and subsequent vesting occurring monthly or quarterly over a threeto four-year period.
Stakeholder Impact
- Shareholders may view the granting of stock options and RSUs as a positive sign, aligning executive interests with company performance.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction for both the restricted stock units and stock options. |
| 03/05/2025 | First vesting date for 25% of the restricted stock units. |
| 02/01/2025 | First vesting date for 25% of the stock options. |
| 03/31/2034 | Expiration date of the stock options. |
| 04/03/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.